Clinical Effects of Buspirone on Intractable Self-Injury in Adults with Mental Retardation
The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three. Standard behavioral observation methods were used to collect data on the number...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 1994-02, Vol.33 (2), p.270-276 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 276 |
|---|---|
| container_issue | 2 |
| container_start_page | 270 |
| container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
| container_volume | 33 |
| creator | RICKETTS, ROBERT W. GOZA, AMANDA B. ELLIS, CYNTHIA R. SINGH, YADHU N. CHAMBERS, SHAREE SINGH, NIRBHAY N. COOKE, JOHN C. |
| description | The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three.
Standard behavioral observation methods were used to collect data on the number of self-injurious responses of the individuals during baseline and several doses of buspirone in an open trial.
When compared with baseline levels, all five individuals showed some response to buspirone, with reductions in self-injury ranging from 13% to 72%, depending on the dose. The most effective dose of buspirone was 30 mg/day for three individuals and 52.5 mg/day for the other two. These individuals were maintained for 6 to 33 weeks on their most effective dose. Coexistent symptoms of anxiety did not predict a favorable response to buspirone therapy.
Buspirone showed a mixed but generally favorable response in controlling intractable self-injury in this and four previous studies reporting similar cases. However, the drug should not be endorsed as a proved treatment for self-injury until similar results have been obtained from well-controlled studies of its efficacy. |
| doi_str_mv | 10.1097/00004583-199402000-00017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76434077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890856709644944</els_id><sourcerecordid>76434077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-41c225dc2428c0ba776d171ff4790553be8f5a57815a25952f2069a789ef1c623</originalsourceid><addsrcrecordid>eNqFkU1rXCEUhqU0pNO0P6EgpXR3G_XqVZfJkDYDCYV-bLoRx3ukDnd0qt6E_PuYzHQW3VQQOZznvBweEcKUfKJEy3PSDheq76jWnLBWde1S-QItqGCyE5yql2hBlCadEoN8hV6XsnlGlDpFp4oKoghZoF_LKcTg7ISvvAdXC04eX85lF3KKgFPEq1izddWuJ8DfYfLdKm7m_IBDxBfjPLWJ-1B_41uItaV8g2rzaGtI8Q068XYq8PbwnqGfn69-LK-7m69fVsuLm85xJmrHqWNMjI5xphxZWymHkUrqPZeaCNGvQXlhhWwrWya0YJ6RQVupNHjqBtafoY_73F1Of2Yo1WxDcTBNNkKai5ED7zmRsoHv_wE3ac6x7WYYZUINnD2lqT3kciolgze7HLY2PxhKzJN789e9Obo3z2Lb6LtD_rzewngcPMhu_Q-Hvi3NuM82ulCOWK8p66Vu2OUegybtLkA2xQWIDsaQ2w-ZMYX_7_IISyOd-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212586422</pqid></control><display><type>article</type><title>Clinical Effects of Buspirone on Intractable Self-Injury in Adults with Mental Retardation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Journals@Ovid Ovid Autoload</source><creator>RICKETTS, ROBERT W. ; GOZA, AMANDA B. ; ELLIS, CYNTHIA R. ; SINGH, YADHU N. ; CHAMBERS, SHAREE ; SINGH, NIRBHAY N. ; COOKE, JOHN C.</creator><creatorcontrib>RICKETTS, ROBERT W. ; GOZA, AMANDA B. ; ELLIS, CYNTHIA R. ; SINGH, YADHU N. ; CHAMBERS, SHAREE ; SINGH, NIRBHAY N. ; COOKE, JOHN C.</creatorcontrib><description>The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three.
Standard behavioral observation methods were used to collect data on the number of self-injurious responses of the individuals during baseline and several doses of buspirone in an open trial.
When compared with baseline levels, all five individuals showed some response to buspirone, with reductions in self-injury ranging from 13% to 72%, depending on the dose. The most effective dose of buspirone was 30 mg/day for three individuals and 52.5 mg/day for the other two. These individuals were maintained for 6 to 33 weeks on their most effective dose. Coexistent symptoms of anxiety did not predict a favorable response to buspirone therapy.
Buspirone showed a mixed but generally favorable response in controlling intractable self-injury in this and four previous studies reporting similar cases. However, the drug should not be endorsed as a proved treatment for self-injury until similar results have been obtained from well-controlled studies of its efficacy.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1097/00004583-199402000-00017</identifier><identifier>PMID: 8150800</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Hagerstown, MD: Elsevier Inc</publisher><subject>Adult ; anxiety ; Behavior disorders ; Biological and medical sciences ; buspirone ; Buspirone - therapeutic use ; Combined Modality Therapy ; Dose-Response Relationship, Drug ; Drug therapy ; Drug Therapy, Combination ; Education of Intellectually Disabled ; Female ; Humans ; Intellectual disabilities ; Male ; Medical sciences ; mental retardation ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Retrospective Studies ; Self-Injurious Behavior - psychology ; Self-Injurious Behavior - rehabilitation ; self-injury ; Thioridazine - therapeutic use</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 1994-02, Vol.33 (2), p.270-276</ispartof><rights>1994 The American Academy of Child and Adolescent Psychiatry</rights><rights>1994 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Feb 1994</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-41c225dc2428c0ba776d171ff4790553be8f5a57815a25952f2069a789ef1c623</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1097/00004583-199402000-00017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3912379$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8150800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RICKETTS, ROBERT W.</creatorcontrib><creatorcontrib>GOZA, AMANDA B.</creatorcontrib><creatorcontrib>ELLIS, CYNTHIA R.</creatorcontrib><creatorcontrib>SINGH, YADHU N.</creatorcontrib><creatorcontrib>CHAMBERS, SHAREE</creatorcontrib><creatorcontrib>SINGH, NIRBHAY N.</creatorcontrib><creatorcontrib>COOKE, JOHN C.</creatorcontrib><title>Clinical Effects of Buspirone on Intractable Self-Injury in Adults with Mental Retardation</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three.
Standard behavioral observation methods were used to collect data on the number of self-injurious responses of the individuals during baseline and several doses of buspirone in an open trial.
When compared with baseline levels, all five individuals showed some response to buspirone, with reductions in self-injury ranging from 13% to 72%, depending on the dose. The most effective dose of buspirone was 30 mg/day for three individuals and 52.5 mg/day for the other two. These individuals were maintained for 6 to 33 weeks on their most effective dose. Coexistent symptoms of anxiety did not predict a favorable response to buspirone therapy.
Buspirone showed a mixed but generally favorable response in controlling intractable self-injury in this and four previous studies reporting similar cases. However, the drug should not be endorsed as a proved treatment for self-injury until similar results have been obtained from well-controlled studies of its efficacy.</description><subject>Adult</subject><subject>anxiety</subject><subject>Behavior disorders</subject><subject>Biological and medical sciences</subject><subject>buspirone</subject><subject>Buspirone - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Education of Intellectually Disabled</subject><subject>Female</subject><subject>Humans</subject><subject>Intellectual disabilities</subject><subject>Male</subject><subject>Medical sciences</subject><subject>mental retardation</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Retrospective Studies</subject><subject>Self-Injurious Behavior - psychology</subject><subject>Self-Injurious Behavior - rehabilitation</subject><subject>self-injury</subject><subject>Thioridazine - therapeutic use</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkU1rXCEUhqU0pNO0P6EgpXR3G_XqVZfJkDYDCYV-bLoRx3ukDnd0qt6E_PuYzHQW3VQQOZznvBweEcKUfKJEy3PSDheq76jWnLBWde1S-QItqGCyE5yql2hBlCadEoN8hV6XsnlGlDpFp4oKoghZoF_LKcTg7ISvvAdXC04eX85lF3KKgFPEq1izddWuJ8DfYfLdKm7m_IBDxBfjPLWJ-1B_41uItaV8g2rzaGtI8Q068XYq8PbwnqGfn69-LK-7m69fVsuLm85xJmrHqWNMjI5xphxZWymHkUrqPZeaCNGvQXlhhWwrWya0YJ6RQVupNHjqBtafoY_73F1Of2Yo1WxDcTBNNkKai5ED7zmRsoHv_wE3ac6x7WYYZUINnD2lqT3kciolgze7HLY2PxhKzJN789e9Obo3z2Lb6LtD_rzewngcPMhu_Q-Hvi3NuM82ulCOWK8p66Vu2OUegybtLkA2xQWIDsaQ2w-ZMYX_7_IISyOd-Q</recordid><startdate>19940201</startdate><enddate>19940201</enddate><creator>RICKETTS, ROBERT W.</creator><creator>GOZA, AMANDA B.</creator><creator>ELLIS, CYNTHIA R.</creator><creator>SINGH, YADHU N.</creator><creator>CHAMBERS, SHAREE</creator><creator>SINGH, NIRBHAY N.</creator><creator>COOKE, JOHN C.</creator><general>Elsevier Inc</general><general>Lippincott</general><general>Elsevier BV</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>19940201</creationdate><title>Clinical Effects of Buspirone on Intractable Self-Injury in Adults with Mental Retardation</title><author>RICKETTS, ROBERT W. ; GOZA, AMANDA B. ; ELLIS, CYNTHIA R. ; SINGH, YADHU N. ; CHAMBERS, SHAREE ; SINGH, NIRBHAY N. ; COOKE, JOHN C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-41c225dc2428c0ba776d171ff4790553be8f5a57815a25952f2069a789ef1c623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>anxiety</topic><topic>Behavior disorders</topic><topic>Biological and medical sciences</topic><topic>buspirone</topic><topic>Buspirone - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Education of Intellectually Disabled</topic><topic>Female</topic><topic>Humans</topic><topic>Intellectual disabilities</topic><topic>Male</topic><topic>Medical sciences</topic><topic>mental retardation</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Retrospective Studies</topic><topic>Self-Injurious Behavior - psychology</topic><topic>Self-Injurious Behavior - rehabilitation</topic><topic>self-injury</topic><topic>Thioridazine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RICKETTS, ROBERT W.</creatorcontrib><creatorcontrib>GOZA, AMANDA B.</creatorcontrib><creatorcontrib>ELLIS, CYNTHIA R.</creatorcontrib><creatorcontrib>SINGH, YADHU N.</creatorcontrib><creatorcontrib>CHAMBERS, SHAREE</creatorcontrib><creatorcontrib>SINGH, NIRBHAY N.</creatorcontrib><creatorcontrib>COOKE, JOHN C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RICKETTS, ROBERT W.</au><au>GOZA, AMANDA B.</au><au>ELLIS, CYNTHIA R.</au><au>SINGH, YADHU N.</au><au>CHAMBERS, SHAREE</au><au>SINGH, NIRBHAY N.</au><au>COOKE, JOHN C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Effects of Buspirone on Intractable Self-Injury in Adults with Mental Retardation</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>1994-02-01</date><risdate>1994</risdate><volume>33</volume><issue>2</issue><spage>270</spage><epage>276</epage><pages>270-276</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three.
Standard behavioral observation methods were used to collect data on the number of self-injurious responses of the individuals during baseline and several doses of buspirone in an open trial.
When compared with baseline levels, all five individuals showed some response to buspirone, with reductions in self-injury ranging from 13% to 72%, depending on the dose. The most effective dose of buspirone was 30 mg/day for three individuals and 52.5 mg/day for the other two. These individuals were maintained for 6 to 33 weeks on their most effective dose. Coexistent symptoms of anxiety did not predict a favorable response to buspirone therapy.
Buspirone showed a mixed but generally favorable response in controlling intractable self-injury in this and four previous studies reporting similar cases. However, the drug should not be endorsed as a proved treatment for self-injury until similar results have been obtained from well-controlled studies of its efficacy.</abstract><cop>Hagerstown, MD</cop><pub>Elsevier Inc</pub><pmid>8150800</pmid><doi>10.1097/00004583-199402000-00017</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-8567 |
| ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 1994-02, Vol.33 (2), p.270-276 |
| issn | 0890-8567 1527-5418 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76434077 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Applied Social Sciences Index & Abstracts (ASSIA); Journals@Ovid Ovid Autoload |
| subjects | Adult anxiety Behavior disorders Biological and medical sciences buspirone Buspirone - therapeutic use Combined Modality Therapy Dose-Response Relationship, Drug Drug therapy Drug Therapy, Combination Education of Intellectually Disabled Female Humans Intellectual disabilities Male Medical sciences mental retardation Neuropharmacology Pharmacology. Drug treatments Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Retrospective Studies Self-Injurious Behavior - psychology Self-Injurious Behavior - rehabilitation self-injury Thioridazine - therapeutic use |
| title | Clinical Effects of Buspirone on Intractable Self-Injury in Adults with Mental Retardation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A17%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Effects%20of%20Buspirone%20on%20Intractable%20Self-Injury%20in%20Adults%20with%20Mental%20Retardation&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=RICKETTS,%20ROBERT%20W.&rft.date=1994-02-01&rft.volume=33&rft.issue=2&rft.spage=270&rft.epage=276&rft.pages=270-276&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1097/00004583-199402000-00017&rft_dat=%3Cproquest_cross%3E76434077%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212586422&rft_id=info:pmid/8150800&rft_els_id=S0890856709644944&rfr_iscdi=true |